UA116517C2 - Фармацевтична композиція для лікування захворювань шлунково-кишкового тракту - Google Patents

Фармацевтична композиція для лікування захворювань шлунково-кишкового тракту

Info

Publication number
UA116517C2
UA116517C2 UAA201707833A UAA201707833A UA116517C2 UA 116517 C2 UA116517 C2 UA 116517C2 UA A201707833 A UAA201707833 A UA A201707833A UA A201707833 A UAA201707833 A UA A201707833A UA 116517 C2 UA116517 C2 UA 116517C2
Authority
UA
Ukraine
Prior art keywords
pharmaceutical composition
gastrointestinal diseases
treating gastrointestinal
sucralfate
ranitidine
Prior art date
Application number
UAA201707833A
Other languages
English (en)
Inventor
Йон Хо Джо
Джун Воо Лее
Original Assignee
Девон Фармасьютікал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55169799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA116517(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Девон Фармасьютікал Ко., Лтд. filed Critical Девон Фармасьютікал Ко., Лтд.
Publication of UA116517C2 publication Critical patent/UA116517C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/245—Bismuth; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Винахід стосується фармацевтичної композиції для лікування захворювань шлунково-кишкового тракту, що містить як активні інгредієнти ранітидин, сукральфат з середнім розміром частинок від 1 до 25 мкм і субцитрат вісмуту із середнім розміром частинок від 5 до 90 мкм.
UAA201707833A 2015-01-30 2016-01-28 Фармацевтична композиція для лікування захворювань шлунково-кишкового тракту UA116517C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20150015339 2015-01-30
KR1020150147513A KR101583452B1 (ko) 2015-01-30 2015-10-22 위장질환 치료용 의약 조성물
PCT/KR2016/000935 WO2016122226A2 (en) 2015-01-30 2016-01-28 A pharmaceutical composition for treating gastrointestinal diseases

Publications (1)

Publication Number Publication Date
UA116517C2 true UA116517C2 (uk) 2018-03-26

Family

ID=55169799

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201707833A UA116517C2 (uk) 2015-01-30 2016-01-28 Фармацевтична композиція для лікування захворювань шлунково-кишкового тракту

Country Status (19)

Country Link
EP (1) EP3250199A4 (uk)
JP (1) JP6419347B2 (uk)
KR (2) KR101583452B1 (uk)
CN (1) CN107205947B (uk)
AR (1) AR105413A1 (uk)
CL (1) CL2017001680A1 (uk)
CO (1) CO2017006222A2 (uk)
EA (1) EA032385B9 (uk)
EC (1) ECSP17038599A (uk)
GE (1) GEP20196941B (uk)
MA (1) MA41432A (uk)
MX (1) MX2017007567A (uk)
MY (1) MY195824A (uk)
PE (1) PE20171340A1 (uk)
PH (1) PH12017550051A1 (uk)
SA (1) SA517382016B1 (uk)
TW (1) TWI635859B (uk)
UA (1) UA116517C2 (uk)
WO (1) WO2016122226A2 (uk)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101988479B1 (ko) 2017-10-11 2019-09-24 (주)휴럼 리트세노라이드를 유효성분으로 하는 헬리코박터 파이로리 균주로부터 유래되는 위장질환 예방 및 치료용 약학 조성물
JP2021518422A (ja) * 2018-04-13 2021-08-02 サムヤン バイオファーマシューティカルズ コーポレイションＳａｍｙａｎｇ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐｏｒａｔｉｏｎ レナリドミドを含む医薬組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3874917T2 (de) * 1987-03-09 1993-03-04 Procter & Gamble Zusammensetzungen und ihre verwendung zur behandlung von magen-darmstoerungen.
US4990610A (en) * 1988-08-25 1991-02-05 Applied Analytical Industries, Inc. Method for preparing high potency sucralfate
EP0403048A3 (en) * 1989-06-14 1991-01-30 Warner-Lambert Company Medicated compositions containing sucralfate and processes for their production
KR970006083B1 (ko) * 1992-01-22 1997-04-23 주식회사 대웅제약 위장질환 치료용 의약 조성물
KR100264547B1 (ko) * 1994-04-26 2000-12-01 나가야마 오사무 수크랄페이트의용융조립제제및그의제조방법
JPH0879097A (ja) * 1994-09-01 1996-03-22 Matsushita Electric Ind Co Ltd 携帯無線機
KR970006083A (ko) 1995-07-06 1997-02-19 한승준 자동차용 카울부의 와이어 고정장치 취부구조
WO1999010000A1 (en) * 1997-08-25 1999-03-04 The Procter & Gamble Company Combined preparations for treating upper gastrointestinal tract distress
AU4655199A (en) 1999-06-21 2001-01-09 Dae Woong Pharmaceutical Co., Ltd. Orally administrable pharmaceutical preparation having therapeutic effect on gastrointestinal disorders comprising coated ranitidine, bismuth subcitrate and sucralfate
JP2006076956A (ja) * 2004-09-10 2006-03-23 Taiyo Yakuhin Kogyo Kk 胃炎の治療・予防用配合剤
WO2010001930A1 (ja) * 2008-07-01 2010-01-07 ライオン株式会社 固形内服製剤
KR20110105223A (ko) * 2010-03-18 2011-09-26 일양약품주식회사 일라프라졸 및 수크랄페이트와 비스무스 제제의 혼합물을 함유하는 위장질환을 예방 또는 치료하기 위한 경구용 약제 조성물
KR20140072673A (ko) * 2012-12-05 2014-06-13 (주)한국파비스제약 경구용 위장질환 치료를 위한 정제

Also Published As

Publication number Publication date
EA201791458A1 (ru) 2017-11-30
GEP20196941B (en) 2019-01-10
MA41432A (fr) 2017-12-05
TWI635859B (zh) 2018-09-21
CN107205947B (zh) 2020-05-22
SA517382016B1 (ar) 2021-03-18
KR20160094268A (ko) 2016-08-09
KR101583452B9 (ko) 2022-05-02
PH12017550051A1 (en) 2018-01-29
CO2017006222A2 (es) 2017-09-20
AR105413A1 (es) 2017-10-04
WO2016122226A3 (en) 2016-09-15
MX2017007567A (es) 2017-10-19
EP3250199A4 (en) 2018-08-08
EP3250199A2 (en) 2017-12-06
KR101583452B1 (ko) 2016-01-11
EA032385B1 (ru) 2019-05-31
EA032385B9 (ru) 2019-07-31
MY195824A (en) 2023-02-22
JP2018503672A (ja) 2018-02-08
JP6419347B2 (ja) 2018-11-07
BR112017013857A2 (pt) 2018-02-27
TW201639559A (zh) 2016-11-16
PE20171340A1 (es) 2017-09-13
WO2016122226A2 (en) 2016-08-04
CN107205947A (zh) 2017-09-26
ECSP17038599A (es) 2017-09-29
CL2017001680A1 (es) 2018-01-12

Similar Documents

Publication Publication Date Title
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
SG11202106160WA (en) Pharmaceutical composition for prevention or treatment of cancer comprising weissella cibaria wikim28 as active ingredient
WO2014147611A8 (en) Quinolines derivatives as novel anticancer agents
CN108026053A8 (zh) 作为mIDH1抑制剂的稠合的咪唑类化合物
EP3312175A4 (en) Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient
PH12020550341A1 (en) Niraparib formulations
PH12017500810A1 (en) Substituted 2,4 diamino-quinoline as new anticancer agents
HK1257615A1 (zh) 用於治療癌症、含有多酚化合物作為活性成分的藥物組合物
EP3034082A4 (en) Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients
EP3539951A4 (en) NOVEL PYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF CANCER AND INFLAMMATORY DISEASES
EP3176163A4 (en) Novel indene derivative, preparation method for same, and pharmaceutical composition, for preventing or treating retinal diseases, containing same as active ingredient
EP3604304A4 (en) PYRROLO-PYRIDINE DERIVATIVE COMPOUND, METHOD OF MANUFACTURING AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE PREVENTION OR TREATMENT OF PROTEIN KINASE-RELATED DISEASES
EP3279210A4 (en) Peptide having anticancer activity, and pharmaceutical composition and dietary supplement composition for preventing and treating cancer, both of which contain same as active ingredient
EP3093023A4 (en) Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing same composition as active ingredient
EP3231436A4 (en) Pharmaceutical composition for prevention or treatment of metabolic disease, comprising bacteroides acidifaciens as effective ingredient
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
EP3336100A4 (en) PEPTIDE WITH EFFECT FOR PREVENTING OR TREATING DISEASES OF THE CENTRAL NERVOUS SYSTEM AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING DISEASES OF THE CENTRAL NERVOUS SYSTEM THEREFOR AS AN ACTIVE SUBSTANCE
PH12017550051A1 (en) A pharmaceutical composition for treating gastrointestinal diseases
EP3311817A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF EYES DISEASES WITH IMATINIB AS AN ACTIVE SUBSTANCE
WO2015001541A3 (en) Pharmaceutical film composition
WO2014125504A3 (en) Pharmaceutical compositions of febuxostat
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.
EP3603656A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF GYNECOLOGICAL DISEASES WITH EXTRACT OF SARCODON IMBRICATUS AS THE ACTIVE SUBSTANCE
EP3610866A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING CANCER, CONTAINING A MALATE-ASPARTATE SHUTTLE INHIBITOR AND ANTI-CANCER DRUG AS ACTIVE SUBSTANCES
PH12017500323A1 (en) P38 map kinase inhibiting indanyl urea compounds